Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching".
about
Electrostatic Interactions of Hsp-organizing Protein Tetratricopeptide Domains with Hsp70 and Hsp90: COMPUTATIONAL ANALYSIS AND PROTEIN ENGINEERINGA combinatorial histidine scanning library approach to engineer highly pH-dependent protein switchesTargeting FcRn for the modulation of antibody dynamicsDesigning cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell bindingEngineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular AccumulationRational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesionConsidering protonation as a posttranslational modification regulating protein structure and function.The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapyEngineered protein A ligands, derived from a histidine-scanning library, facilitate the affinity purification of IgG under mild acidic conditions.Design of pH sensitive binding proteins from the hyperthermophilic Sso7d scaffoldFlipping the Switch on Clathrin-Mediated Endocytosis using Thermally Responsive Protein Microdomains.Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexesPreclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast displaypH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.Engineering pH responsive fibronectin domains for biomedical applications.Engineering growth factors for regenerative medicine applications.Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9Isolation of a pH-Sensitive IgNAR Variable Domain from a Yeast-Displayed, Histidine-Doped Master Library.Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization.Novel method for probing the specificity binding profile of ligands: applications to HIV protease.Cellular level models as tools for cytokine design.Direct Calculation of Protein Fitness Landscapes through Computational Protein Design.Carbohydrate recognition by the antiviral lectin cyanovirin-N.In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP).Integrative meta-modeling identifies endocytic vesicles, late endosome and the nucleus as the cellular compartments primarily directing RTK signaling.Inhibition of transferrin iron release increases in vitro drug carrier efficacyQuerying quantitative logic models (Q2LM) to study intracellular signaling networks and cell-cytokine interactionsRational design of new binding specificity by simultaneous mutagenesis of calmodulin and a target peptideEffects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins.Release factors eRF1 and RF2: a universal mechanism controls the large conformational changes.Fast gap-free enumeration of conformations and sequences for protein design.pH Dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor.Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences.
P2860
Q27646517-D3D5CDB6-DA0D-4025-B3BB-9D47802B579EQ27670852-DF6A37C5-05B9-4957-93D0-EFEE708AA99EQ28080589-F5E12DE3-65F8-4670-9473-7D0397F53A1AQ28252009-596EFD76-A53B-44E2-AB0A-9BD25A07A6E1Q28551823-49E2E71E-530C-4CE5-AAD3-3FF631DD0870Q28914750-6DE194FB-3DDD-4AF3-9CF7-AEA7AB79CD93Q30427740-45E11872-61FF-4220-ADC3-20127742B11CQ30566003-362F606A-0986-4821-8011-152756CD8AD2Q33779567-D121B7C6-734D-4B23-AC7B-548C8D133690Q33936317-CA0516A2-2D83-4AE5-901B-89CEF50C0875Q34473740-23347EE7-F800-425B-A47A-BE4CF6661110Q34534875-669050A1-C406-404F-ADC8-2C32937A7AC8Q34751465-F3C30DF3-88CF-4A77-A543-8AEDFD61BB32Q35067889-DE261438-99EF-4B48-87ED-2ABF183A9328Q35098849-C95CD5D1-2367-41EF-89AF-FBE11002B67AQ35194805-EA0B5AAE-C883-408E-B552-2F3956B8122DQ35530272-62F91896-594F-4CE5-9F55-8E875FD4ECD8Q35602819-DEF92488-58BA-4124-8F7B-890CCE93916CQ35770463-0ACE63AF-B52D-401F-8728-12C5EF139DB7Q35837394-08CEBC08-F8F5-414E-AABE-97826B4987F9Q35879455-FE56F11D-02E4-438B-8E6C-F04A9D06457EQ35912713-3E0E6CF0-23B7-4877-9DC5-59817285124CQ36130660-B4C4A720-2F4F-4882-B666-6B6FEBD3D555Q36344445-3DE8271E-1BCB-409D-B416-6FCF143182CDQ36393660-161963CA-9ABD-4345-B8BD-658D58425FDCQ36460364-B852221A-44F4-4EE4-AA83-380494F5DA05Q36492955-2EA5CFFF-7284-47C9-819E-E33109AD4F80Q37129823-5BBE02E9-39EB-40E5-81C4-C7DB3399D06FQ38652655-ACD9E080-A353-438F-B006-72EEB8E29C4EQ40351752-D53F4DB1-5974-4298-94A2-DEB61CB941ABQ40463360-D0CFC98F-4DB5-4D3E-AEF1-21302C82AE3AQ41831883-15F84695-4A44-4F52-ACD7-2790B8505F91Q41887989-0C9FFDD4-C1FB-46AC-8513-88806A5F3744Q41949099-8A959188-995E-4C65-B7ED-36030F300333Q42572918-E9208255-7BCF-4A80-8F40-5C05DD3BD5D6Q42637863-CCB15E59-DEAB-4CE1-BFBB-2F55BE494D48Q42695246-15C08722-D89C-49D1-A0BB-BD236F7CCD15Q42909689-3D77978F-4F8C-40D6-B9DF-EA7EC91840CDQ43635728-3E998BF6-4445-414F-A062-80B24AF1AF01Q44652104-F20F6BDC-97BA-4FBE-BACD-2417280D4E02
P2860
Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching".
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Rational cytokine design for i ...... tivated "histidine switching".
@en
Rational cytokine design for i ...... tivated "histidine switching".
@nl
type
label
Rational cytokine design for i ...... tivated "histidine switching".
@en
Rational cytokine design for i ...... tivated "histidine switching".
@nl
prefLabel
Rational cytokine design for i ...... tivated "histidine switching".
@en
Rational cytokine design for i ...... tivated "histidine switching".
@nl
P2093
P2860
P356
P1433
P1476
Rational cytokine design for i ...... ctivated "histidine switching"
@en
P2093
Casim A Sarkar
Douglas A Lauffenburger
Thomas C Boone
Thomas Horan
P2860
P2888
P304
P356
10.1038/NBT725
P577
2002-08-05T00:00:00Z